The role of immune checkpoint inhibitors in the first-line treatment for patients with advanced biliary tract cancer: a systematic review and meta-analysis of randomized trials
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 August 2024.
All research outputs
#20,889,917
of 26,538,769 outputs
Outputs from Frontiers in oncology
#9,836
of 23,241 outputs
Outputs of similar age
#159,065
of 261,735 outputs
Outputs of similar age from Frontiers in oncology
#60
of 325 outputs
Altmetric has tracked 26,538,769 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 23,241 research outputs from this source. They receive a mean Attention Score of 3.2. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 261,735 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 325 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.
